Crossmark

Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update

Crossref DOI link: https://doi.org/10.1007/s40520-022-02261-2

Published Online: 2022-11-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Messina, Osvaldo Daniel

Vidal, Maritza https://orcid.org/0000-0001-8494-5260
Torres, Jorge A Morales

Vidal, Luis Fernando

Arguissain, Constanza

Pereira, Rosa María

Clark, Patricia

Cerdas Perez, Sonia

Campusano, Claudia

Lazaretti-Castro, Marise

Zerbini, Cristiano

Scali, Juan J.

Mendez Sanchez, Lucia

Peralta-Pedrero, Maria L.

Cavallo, Andrea

Valdivia Ibarra, Francisco J.

Hernandez Pérez, Talina
License Information

Text and Data Mining valid from 2022-11-09

Version of Record valid from 2022-11-09
More Information

Article History

Received: 17 August 2022

Accepted: 16 September 2022

First Online: 9 November 2022

Declarations

:

: OD Messina received honoraria from Amgen, E Lilly and Pfizer. S Cerdas Perez received honoraria from Amgen, Novo Nordisk, MSD, AstraZeneca and Faes Farma. The other authors declare no conflict of interests.

Document is current

Any future updates will be listed below